| Year |
Citation |
Score |
| 2024 |
Iskander R, Moyer H, Fergusson D, McGrath S, Benedetti A, Kimmelman J. The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of Internal Medicine. PMID 38684102 DOI: 10.7326/M23-2515 |
0.352 |
|
| 2023 |
Bicer S, Hutchinson N, Feldhake E, Nelson A, Oliviero E, Waligóra M, Kimmelman J. Timing for First-in-Minor Clinical Trials of New Cancer Drugs. The Journal of Pediatrics. 113705. PMID 37657661 DOI: 10.1016/j.jpeds.2023.113705 |
0.3 |
|
| 2022 |
Ouimet C, Bouche G, Kimmelman J. Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study. Plos One. 17: e0274115. PMID 36094914 DOI: 10.1371/journal.pone.0274115 |
0.323 |
|
| 2022 |
Hutchinson N, Moyer H, Zarin DA, Kimmelman J. The proportion of randomized controlled trials that inform clinical practice. Elife. 11. PMID 35975784 DOI: 10.7554/eLife.79491 |
0.351 |
|
| 2022 |
Sheng J, Feldhake E, Zarin DA, Kimmelman J. Completeness of clinical evidence citation in trial protocols: A cross-sectional analysis. Med (New York, N.Y.). 3: 335-343.e6. PMID 35584654 DOI: 10.1016/j.medj.2022.03.002 |
0.327 |
|
| 2022 |
Kim SY, Kimmelman J. Practical steps to identifying the research risk of pragmatic trials. Clinical Trials (London, England). 19: 211-216. PMID 35348360 DOI: 10.1177/17407745211063476 |
0.37 |
|
| 2022 |
Bittlinger M, Bicer S, Peppercorn J, Kimmelman J. Ethical Considerations for Phase I Trials in Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102125. PMID 35275736 DOI: 10.1200/JCO.21.02125 |
0.375 |
|
| 2021 |
Kane PB, Bittlinger M, Kimmelman J. Individualized therapy trials: navigating patient care, research goals and ethics. Nature Medicine. 27: 1679-1686. PMID 34642487 DOI: 10.1038/s41591-021-01519-y |
0.36 |
|
| 2020 |
Kimmelman J. What Is Human Research For? Reflections on the Omission of Scientific Integrity from the Belmont Report Perspectives in Biology and Medicine. 63: 251-261. PMID 33416651 DOI: 10.1353/Pbm.2020.0017 |
0.321 |
|
| 2020 |
Lalu MM, Montroy J, Begley CG, Bubela T, Hunniford V, Ripsman D, Wesch N, Kimmelman J, Macleod M, Moher D, Tieu A, Sikora L, Fergusson DA. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. F1000research. 9: 485. PMID 33123348 DOI: 10.12688/F1000Research.23663.1 |
0.426 |
|
| 2020 |
Benjamin DM, Mandel DR, Barnes T, Krzyzanowska MK, Leighl N, Tannock IF, Kimmelman J. Can Oncologists Predict the Efficacy of Treatments in Randomized Trials? The Oncologist. PMID 32936509 DOI: 10.1634/Theoncologist.2020-0054 |
0.42 |
|
| 2020 |
Gumnit E, Feustel AC, Wong S, Bosan R, Hutchinson N, Kimmelman J. The proportion of North American cancer trials that evaluate novel targets. Investigational New Drugs. PMID 32681475 DOI: 10.1007/S10637-020-00971-W |
0.433 |
|
| 2020 |
Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M. Clinical development success rates and social value of pediatric Phase 1 trials in oncology. Plos One. 15: 1-12. PMID 32579564 DOI: 10.1371/Journal.Pone.0234911 |
0.461 |
|
| 2020 |
Atanasov P, Diamantaras A, MacPherson A, Vinarov E, Benjamin DM, Shrier I, Paul F, Dirnagl U, Kimmelman J. Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. Neurology. PMID 32546652 DOI: 10.1212/Wnl.0000000000009819 |
0.361 |
|
| 2020 |
Montroy J, Lalu MM, Auer RC, Grigor E, Mazzarello S, Carrier M, Kimmelman J, Fergusson DA. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 120: 832-846. PMID 32369854 DOI: 10.1055/S-0040-1709712 |
0.3 |
|
| 2020 |
Kane PB, Benjamin DM, Barker RA, Lang AE, Sherer T, Kimmelman J. Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. Journal of Parkinson's Disease. PMID 32333550 DOI: 10.3233/Jpd-201933 |
0.317 |
|
| 2020 |
London AJ, Kimmelman J. Against pandemic research exceptionalism. Science (New York, N.Y.). 368: 476-477. PMID 32327600 DOI: 10.1126/Science.Abc1731 |
0.303 |
|
| 2020 |
Zhang SX, Fergusson D, Kimmelman J. Proportion of Patients in Phase 1 Oncology Trials Receiving Treatments that are Ultimately Approved. Journal of the National Cancer Institute. PMID 32239146 DOI: 10.1093/Jnci/Djaa044 |
0.387 |
|
| 2020 |
Carlisle BG, Doussau A, Kimmelman J. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. Bmj Open. 10: e034306. PMID 32071183 DOI: 10.1136/Bmjopen-2019-034306 |
0.45 |
|
| 2020 |
Federico CA, Mogil JS, Ramsay T, Fergusson DA, Kimmelman J. A systematic review and meta-analysis of pregabalin preclinical studies. Pain. PMID 31977931 DOI: 10.1097/J.Pain.0000000000001749 |
0.31 |
|
| 2020 |
Kane PB, Kim SYH, Kimmelman J. What Research Ethics (Often) Gets Wrong about Minimal Risk. The American Journal of Bioethics : Ajob. 20: 42-44. PMID 31910134 DOI: 10.1080/15265161.2019.1687789 |
0.332 |
|
| 2020 |
Carlisle BG, Doussau A, Kimmelman J. Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials (London, England). 17: 18-29. PMID 31580145 DOI: 10.1177/1740774519873883 |
0.414 |
|
| 2019 |
Hutchinson N, Vinarov E, Iasonos A, Kimmelman J. Ethical and Policy Issues for Seamless Phase I Oncology Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902456. PMID 31877086 DOI: 10.1200/Jco.19.02456 |
0.386 |
|
| 2019 |
Thombs BD, Levis AW, Azar M, Saadat N, Riehm KE, Sanchez TA, Chiovitti MJ, Rice DB, Levis B, Fedoruk C, Lyubenova A, Malo Vázquez de Lara AL, Kloda LA, Benedetti A, Shrier I, ... ... Kimmelman J, et al. Group Sample Sizes in Non-Regulated Health Care Intervention Trials Described as Randomized Controlled Trials were Overly Similar. Journal of Clinical Epidemiology. PMID 31866472 DOI: 10.1016/J.Jclinepi.2019.12.011 |
0.33 |
|
| 2019 |
Kimmelman J. Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. Nature Reviews. Clinical Oncology. PMID 31857690 DOI: 10.1038/S41571-019-0312-3 |
0.388 |
|
| 2019 |
Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J. Risks and benefits of unapproved, disease-modifying treatments for neurodegenerative disease. Neurology. PMID 31792092 DOI: 10.1212/Wnl.0000000000008699 |
0.328 |
|
| 2019 |
Sarvas H, Carlisle B, Dolter S, Vinarov E, Kimmelman J. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute. PMID 31722417 DOI: 10.1093/Jnci/Djz212 |
0.374 |
|
| 2019 |
Carlisle BG, Zheng T, Kimmelman J. Imatinib and the long tail of targeted drug development. Nature Reviews. Clinical Oncology. PMID 31649355 DOI: 10.1038/S41571-019-0287-0 |
0.321 |
|
| 2019 |
Kimmelman J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nature Reviews. Clinical Oncology. PMID 31471566 DOI: 10.1038/S41571-019-0264-7 |
0.423 |
|
| 2019 |
London AJ, Kimmelman J. Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. The Hastings Center Report. 49: 31-41. PMID 31429954 DOI: 10.1002/Hast.1034 |
0.49 |
|
| 2019 |
Eyal N, Kimmelman J, Holtzman LG, Lipsitch M. Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical Trials (London, England). 1740774519862783. PMID 31368813 DOI: 10.1177/1740774519862783 |
0.434 |
|
| 2019 |
Kimmelman J. Organ donor intervention trials and the ethical challenge of bystander organ recipients. Clinical Trials (London, England). 16: 461-462. PMID 31368792 DOI: 10.1177/1740774519862777 |
0.341 |
|
| 2019 |
Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. Jama. PMID 31343666 DOI: 10.1001/Jama.2019.9892 |
0.421 |
|
| 2019 |
Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo JS, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C, et al. Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. Molecular Therapy Oncolytics. 14: 179-187. PMID 31276026 DOI: 10.1016/J.Omto.2019.05.004 |
0.363 |
|
| 2019 |
MacPherson A, Kimmelman J. Ethical development of stem-cell-based interventions. Nature Medicine. PMID 31270501 DOI: 10.1038/S41591-019-0511-6 |
0.407 |
|
| 2019 |
Pratte M, Ganeshamoorthy S, Carlisle B, Kimmelman J. How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence? International Journal of Cancer. 145: 3370-3375. PMID 31087646 DOI: 10.1002/Ijc.32405 |
0.471 |
|
| 2019 |
Cook JA, Fergusson DA, Ford I, Gonen M, Kimmelman J, Korn EL, Begg CB. There is still a place for significance testing in clinical trials. Clinical Trials (London, England). 1740774519846504. PMID 31068002 DOI: 10.1177/1740774519846504 |
0.401 |
|
| 2019 |
Kimmelman J, Waligora M, Lynch HF. Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials-Reply. Jama Pediatrics. PMID 31009030 DOI: 10.1001/Jamapediatrics.2019.0797 |
0.397 |
|
| 2019 |
Azar M, Riehm KE, Saadat N, Sanchez T, Chiovitti M, Qi L, Rice DB, Levis B, Fedoruk C, Levis AW, Kloda LA, Kimmelman J, Benedetti A, Thombs BD. Evaluation of Journal Registration Policies and Prospective Registration of Randomized Clinical Trials of Nonregulated Health Care Interventions. Jama Internal Medicine. PMID 30855655 DOI: 10.1001/Jamainternmed.2018.8009 |
0.35 |
|
| 2018 |
Zarzeczny A, Atkins H, Illes J, Kimmelman J, Master Z, Robillard JM, Snyder J, Turner L, Zettler PJ, Caulfield T. The stem cell market and policy options: a call for clarity. Journal of Law and the Biosciences. 5: 743-758. PMID 31143461 DOI: 10.1093/Jlb/Lsy025 |
0.367 |
|
| 2018 |
Federico CA, Wang T, Doussau A, Mogil JS, Fergusson D, Kimmelman J. Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review. Jama Internal Medicine. PMID 30477010 DOI: 10.1001/Jamainternmed.2018.5705 |
0.471 |
|
| 2018 |
Kimmelman J, Waligora M, Lynch HF. Participant Protection in Phase 1 Pediatric Cancer Trials. Jama Pediatrics. PMID 30419141 DOI: 10.1001/Jamapediatrics.2018.3629 |
0.372 |
|
| 2018 |
Langhof H, Chin WWL, Wieschowski S, Federico C, Kimmelman J, Strech D. Preclinical efficacy in therapeutic area guidelines from FDA and EMA: A cross-sectional study. British Journal of Pharmacology. PMID 30153701 DOI: 10.1111/Bph.14485 |
0.349 |
|
| 2018 |
Shah SK, Kimmelman J, Lyerly AD, Lynch HF, Miller FG, Palacios R, Pardo CA, Zorrilla C. Response-Evaluating human trials: FDA's role. Science (New York, N.Y.). 360: 1308-1309. PMID 29930129 DOI: 10.1126/Science.Aau0865 |
0.369 |
|
| 2018 |
Yarborough M, Bredenoord A, D'Abramo F, Joyce NC, Kimmelman J, Ogbogu U, Sena E, Strech D, Dirnagl U. The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials. Plos Biology. 16: e2006343. PMID 29874243 DOI: 10.1371/Journal.Pbio.2006343 |
0.41 |
|
| 2018 |
Kimmelman J. Better to be in The Placebo Arm for Trials of Neurological Therapies? Cell Transplantation. 27: 677-681. PMID 29855198 DOI: 10.1177/0963689718755708 |
0.457 |
|
| 2018 |
Shah SK, Kimmelman J, Lyerly AD, Lynch HF, Miller FG, Palacios R, Pardo CA, Zorrilla C. Bystander risk, social value, and ethics of human research. Science (New York, N.Y.). 360: 158-159. PMID 29650663 DOI: 10.1126/Science.Aaq0917 |
0.394 |
|
| 2018 |
London AJ, Kimmelman J. Clinical Trials in Medical Center Advertising. Jama Oncology. 4: 769-770. PMID 29621381 DOI: 10.1001/Jamaoncol.2018.0181 |
0.375 |
|
| 2018 |
Wieschowski S, Chin WWL, Federico C, Sievers S, Kimmelman J, Strech D. Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment? Plos Biology. 16: e2004879. PMID 29621228 DOI: 10.1371/Journal.Pbio.2004879 |
0.413 |
|
| 2018 |
Carlisle B, Federico CA, Kimmelman J. Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval. Bmj (Clinical Research Ed.). 360: k959. PMID 29559429 DOI: 10.1136/Bmj.K959 |
0.426 |
|
| 2018 |
Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. Plos Medicine. 15: e1002505. PMID 29462168 DOI: 10.1371/Journal.Pmed.1002505 |
0.376 |
|
| 2017 |
Benjamin D, Mandel DR, Kimmelman J. Can cancer researchers accurately judge whether preclinical reports will reproduce? Plos Biology. 15: e2002212. PMID 28662052 DOI: 10.1371/Journal.Pbio.2002212 |
0.349 |
|
| 2017 |
Hakala AK, Fergusson D, Kimmelman J. Nonpublication of trial results for new neurological drugs: A systematic review. Annals of Neurology. 81: 782-789. PMID 28486773 DOI: 10.1002/Ana.24952 |
0.383 |
|
| 2017 |
Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ. Burdensome Research Procedures in Trials: Why Less Is More. Journal of the National Cancer Institute. 109. PMID 28376159 DOI: 10.1093/Jnci/Djw315 |
0.379 |
|
| 2017 |
Neumann K, Grittner U, Piper SK, Rex A, Florez-Vargas O, Karystianis G, Schneider A, Wellwood I, Siegerink B, Ioannidis JP, Kimmelman J, Dirnagl U. Increasing efficiency of preclinical research by group sequential designs. Plos Biology. 15: e2001307. PMID 28282371 DOI: 10.1371/Journal.Pbio.2001307 |
0.326 |
|
| 2017 |
Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. Plos Biology. 15: e2000487. PMID 28158308 DOI: 10.1371/Journal.Pbio.2000487 |
0.429 |
|
| 2017 |
Kimmelman J, Federico C. Consider drug efficacy before first-in-human trials. Nature. 542: 25-27. PMID 28150789 DOI: 10.1038/542025A |
0.395 |
|
| 2017 |
Barsanti-Innes B, Hey SP, Kimmelman J. The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. The Oncologist. 22: 89-96. PMID 28126916 DOI: 10.1634/Theoncologist.2016-0188 |
0.347 |
|
| 2016 |
Kimmelman J. Is Participation in Cancer Phase I Trials Really Therapeutic? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27646944 DOI: 10.1200/Jco.2016.67.9902 |
0.378 |
|
| 2016 |
Mattina J, MacKinnon N, Henderson VC, Fergusson D, Kimmelman J. Design and Reporting of Targeted Anti-Cancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. Cancer Research. PMID 27261504 DOI: 10.1158/0008-5472.Can-15-3455 |
0.366 |
|
| 2016 |
Hey SP, Kimmelman J. Do We Know Whether Researchers and Reviewers are Estimating Risk and Benefit Accurately? Bioethics. 30: 609-17. PMID 27197044 DOI: 10.1111/Bioe.12260 |
0.346 |
|
| 2016 |
Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, ... ... Kimmelman J, et al. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem Cell Reports. PMID 27185282 DOI: 10.1016/J.Stemcr.2016.05.001 |
0.367 |
|
| 2016 |
Kimmelman J, Heslop HE, Sugarman J, Studer L, Benvenisty N, Caulfield T, Hyun I, Murry CE, Sipp D, Daley GQ. New ISSCR guidelines: clinical translation of stem cell research. Lancet (London, England). PMID 27179752 DOI: 10.1016/S0140-6736(16)30390-7 |
0.353 |
|
| 2016 |
Caulfield T, Sipp D, Murry CE, Daley GQ, Kimmelman J. SCIENTIFIC COMMUNITY. Confronting stem cell hype. Science (New York, N.Y.). 352: 776-7. PMID 27174977 DOI: 10.1126/Science.Aaf4620 |
0.362 |
|
| 2016 |
Grankvist H, Kimmelman J. How do researchers decide early clinical trials? Medicine, Health Care, and Philosophy. 19: 191-8. PMID 26833467 DOI: 10.1007/S11019-016-9685-6 |
0.469 |
|
| 2016 |
Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. Journal of the National Cancer Institute. 108. PMID 26547927 DOI: 10.1093/Jnci/Djv292 |
0.329 |
|
| 2016 |
Kimmelman J, Henderson V. Assessing risk/benefit for trials using preclinical evidence: a proposal. Journal of Medical Ethics. 42: 50-3. PMID 26463620 DOI: 10.1136/Medethics-2015-102882 |
0.423 |
|
| 2015 |
London AJ, Kimmelman J. Why clinical translation cannot succeed without failure. Elife. 4: e12844. PMID 26599839 DOI: 10.7554/Elife.12844 |
0.354 |
|
| 2015 |
Henderson VC, Demko N, Hakala A, MacKinnon N, Federico CA, Fergusson D, Kimmelman J. A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife. 4: e08351. PMID 26460544 DOI: 10.7554/Elife.08351 |
0.386 |
|
| 2015 |
Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. PMID 26307858 DOI: 10.1097/J.Pain.0000000000000333 |
0.385 |
|
| 2015 |
Wenner DM, Kimmelman J, London AJ. Patient-Funded Trials: Opportunity or Liability? Cell Stem Cell. 17: 135-7. PMID 26253199 DOI: 10.1016/J.Stem.2015.07.016 |
0.458 |
|
| 2015 |
Kimmelman J. The secret realm of phase I trials in healthy volunteers. Bmj (Clinical Research Ed.). 350: h3444. PMID 26116281 DOI: 10.1136/Bmj.H3444 |
0.425 |
|
| 2015 |
Kimmelman J. Ethics of Cancer Gene Transfer Clinical Research. Methods in Molecular Biology (Clifton, N.J.). 1317: 263-85. PMID 26072412 DOI: 10.1007/978-1-4939-2727-2_15 |
0.32 |
|
| 2015 |
Hakala A, Kimmelman J, Carlisle B, Freeman G, Fergusson D. Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. Bmj (Clinical Research Ed.). 350: h1116. PMID 25752879 DOI: 10.1136/Bmj.H1116 |
0.419 |
|
| 2015 |
Hey SP, Kimmelman J. Are outcome-adaptive allocation trials ethical? Clinical Trials (London, England). 12: 102-6. PMID 25649106 DOI: 10.1177/1740774514563583 |
0.398 |
|
| 2015 |
Kimmelman J, London AJ. The structure of clinical translation: efficiency, information, and ethics. The Hastings Center Report. 45: 27-39. PMID 25628068 DOI: 10.1002/Hast.433 |
0.334 |
|
| 2015 |
Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clinical Trials (London, England). 12: 77-83. PMID 25475878 DOI: 10.1177/1740774514558307 |
0.488 |
|
| 2015 |
Henderson VC, Demko N, Hakala A, MacKinnon N, Federico CA, Fergusson D, Kimmelman J. Author response: A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib Elife. DOI: 10.7554/Elife.08351.015 |
0.382 |
|
| 2014 |
Hey SP, Kimmelman J. The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Institute of Ethics Journal. 24: 121-39. PMID 25109092 DOI: 10.1353/Ken.2014.0017 |
0.438 |
|
| 2014 |
Kimmelman J, Mogil JS, Dirnagl U. Distinguishing between exploratory and confirmatory preclinical research will improve translation. Plos Biology. 12: e1001863. PMID 24844265 DOI: 10.1371/Journal.Pbio.1001863 |
0.352 |
|
| 2014 |
Federico CA, Carlisle B, Kimmelman J, Fergusson DA. Late, never or non-existent: the inaccessibility of preclinical evidence for new drugs. British Journal of Pharmacology. 171: 4247-4254. PMID 24825131 DOI: 10.1111/Bph.12771 |
0.418 |
|
| 2014 |
Hey SP, Kimmelman J. The questionable use of unequal allocation in confirmatory trials. Neurology. 82: 77-9. PMID 24306005 DOI: 10.1212/01.Wnl.0000438226.10353.1C |
0.425 |
|
| 2014 |
Anderson JA, Kimmelman J. Are phase 1 trials therapeutic? Risk, ethics, and division of labor. Bioethics. 28: 138-46. PMID 22681632 DOI: 10.1111/J.1467-8519.2012.01979.X |
0.48 |
|
| 2013 |
Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. Plos Medicine. 10: e1001489. PMID 23935460 DOI: 10.1371/Journal.Pmed.1001489 |
0.398 |
|
| 2013 |
Freeman GA, Kimmelman J, Dancey J, Monzon JG. Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials. British Journal of Cancer. 109: 897-908. PMID 23887602 DOI: 10.1038/Bjc.2013.417 |
0.395 |
|
| 2013 |
Hey SP, Kimmelman J. Ethics, error, and initial trials of efficacy. Science Translational Medicine. 5: 184fs16. PMID 23658242 DOI: 10.1126/Scitranslmed.3005684 |
0.404 |
|
| 2013 |
Haimes E, Skene L, Ballantyne AJ, Caulfield T, Goldstein LS, Hyun I, Kimmelman J, Robert JS, Roxland BE, Scott CT, Solbakk JH, Sugarman J, Taylor PL, Testa G. Position statement on the provision and procurement of human eggs for stem cell research. Cell Stem Cell. 12: 285-91. PMID 23472870 DOI: 10.1016/J.Stem.2013.02.002 |
0.307 |
|
| 2012 |
Kimmelman J. Beyond human subjects: risk, ethics, and clinical development of nanomedicines. The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics. 40: 841-7. PMID 23289686 DOI: 10.1111/J.1748-720X.2012.00712.X |
0.398 |
|
| 2012 |
Kato K, Kimmelman J, Robert J, Sipp D, Sugarman J. Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR Tenth Annual Meeting. Cell Stem Cell. 11: 765-7. PMID 23217422 DOI: 10.1016/J.Stem.2012.11.004 |
0.375 |
|
| 2012 |
Kimmelman J. A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. Trials. 13: 173. PMID 22999017 DOI: 10.1186/1745-6215-13-173 |
0.38 |
|
| 2012 |
Freeman GA, Kimmelman J. Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6478-84. PMID 22912391 DOI: 10.1158/1078-0432.Ccr-12-1384 |
0.372 |
|
| 2012 |
Kimmelman J, Anderson JA. Should preclinical studies be registered? Nature Biotechnology. 30: 488-9. PMID 22678379 DOI: 10.1038/Nbt.2261 |
0.329 |
|
| 2012 |
London AJ, Kimmelman J, Carlisle B. Research ethics. Rethinking research ethics: the case of postmarketing trials. Science (New York, N.Y.). 336: 544-5. PMID 22556237 DOI: 10.1126/Science.1216086 |
0.39 |
|
| 2012 |
Kimmelman J. Ethics, ambiguity aversion, and the review of complex translational clinical trials. Bioethics. 26: 242-50. PMID 21241343 DOI: 10.1111/J.1467-8519.2010.01856.X |
0.429 |
|
| 2011 |
Racine E, Northoff G, Menon RS, Kimmelman J, Illes J. A canadian perspective on ethics review and neuroimaging: tensions and solutions. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 38: 572-9. PMID 21672697 DOI: 10.1017/S0317167100012117 |
0.363 |
|
| 2011 |
Kimmelman J, London AJ. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. Plos Medicine. 8: e1001010. PMID 21423344 DOI: 10.1371/Journal.Pmed.1001010 |
0.492 |
|
| 2010 |
Anderson JA, Kimmelman J. Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Institute of Ethics Journal. 20: 75-98. PMID 20506695 DOI: 10.1353/Ken.0.0307 |
0.45 |
|
| 2010 |
London AJ, Kimmelman J, Emborg ME. Beyond access vs. protection in trials of innovative therapies Science. 328: 829-830. PMID 20466907 DOI: 10.1126/Science.1189369 |
0.423 |
|
| 2010 |
Brehaut JC, Fergusson DA, Kimmelman J, Shojania KG, Saginur R, Elwyn G. Using decision aids may improve informed consent for research. Contemporary Clinical Trials. 31: 218-20. PMID 20156597 DOI: 10.1016/J.Cct.2010.02.002 |
0.302 |
|
| 2009 |
Kimmelman J, London AJ, Ravina B, Ramsay T, Bernstein M, Fine A, Stahnisch FW, Emborg ME. Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1893-901. PMID 19672990 DOI: 10.1002/Mds.22712 |
0.405 |
|
| 2009 |
Kimmelman J. Ethics of cancer gene transfer clinical research. Methods in Molecular Biology (Clifton, N.J.). 542: 423-45. PMID 19565916 DOI: 10.1007/978-1-59745-561-9_23 |
0.333 |
|
| 2009 |
Kimmelman J. Battling a Thousand Points of Might Hastings Center Report. 39: 3-3. PMID 19213180 DOI: 10.1353/Hcr.0.0092 |
0.357 |
|
| 2009 |
Kimmelman J, Weijer C, Meslin EM. Helsinki discords: FDA, ethics, and international drug trials The Lancet. 373: 13-14. PMID 19121708 DOI: 10.1016/S0140-6736(08)61936-4 |
0.409 |
|
| 2008 |
Brehaut JC, Lott A, Fergusson DA, Shojania KG, Kimmelman J, Saginur R. Can patient decision aids help people make good decisions about participating in clinical trials? A study protocol. Implementation Science : Is. 3: 38. PMID 18651981 DOI: 10.1186/1748-5908-3-38 |
0.334 |
|
| 2008 |
London AJ, Kimmelman J. Justice in translation: from bench to bedside in the developing world The Lancet. 372: 82-85. PMID 18603162 DOI: 10.1016/S0140-6736(08)60996-4 |
0.381 |
|
| 2008 |
Kimmelman J. The ethics of human gene transfer Nature Reviews Genetics. 9: 239-244. PMID 18278058 DOI: 10.1038/Nrg2317 |
0.315 |
|
| 2007 |
Kimmelman J. The therapeutic misconception at 25: treatment, research, and confusion. Hastings Center Report. 37: 36-42. PMID 18179103 DOI: 10.1353/Hcr.2007.0092 |
0.469 |
|
| 2007 |
Kimmelman J. Ethics at phase 0: clarifying the issues. Journal of Law Medicine & Ethics. 35: 727-733. PMID 18076522 DOI: 10.1111/J.1748-720X.2007.00194.X |
0.454 |
|
| 2007 |
Kimmelman J. Clinical trials and SCID row: the ethics of phase 1 trials in the developing world. Developing World Bioethics. 7: 128-35. PMID 18021117 DOI: 10.1111/j.1471-8847.2006.00154.x |
0.364 |
|
| 2007 |
Kimmelman J. Missing the forest: further thoughts on the ethics of bystander risk in medical research. Cambridge Quarterly of Healthcare Ethics. 16: 483. PMID 18018930 DOI: 10.1017/S0963180107070648 |
0.303 |
|
| 2007 |
Kimmelman J. Staunch protections: the ethics of haemophilia gene transfer research. Haemophilia. 14: 5-14. PMID 18005150 DOI: 10.1111/J.1365-2516.2007.01567.X |
0.477 |
|
| 2007 |
Kimmelman J. Stable Ethics: Enrolling Non-Treatment-Refractory Volunteers in Novel Gene Transfer Trials Molecular Therapy. 15: 1904-1906. PMID 17948045 DOI: 10.1038/Sj.Mt.6300316 |
0.308 |
|
| 2007 |
Kimmelman J, Nalbantoglu J. Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Research. 67: 4541-4. PMID 17510377 DOI: 10.1158/0008-5472.Can-06-3792 |
0.373 |
|
| 2007 |
Kimmelman J. Inventors as investigators: the ethics of patents in clinical trials. Academic Medicine. 82: 24-31. PMID 17198287 DOI: 10.1097/01.Acm.0000250027.48685.Ca |
0.397 |
|
| 2007 |
Kimmelman J. Clinical trials and SCID row: the ethics of phase 1 trials in the developing world. Developing World Bioethics. 7: 128-135. DOI: 10.1111/Dewb_154.X |
0.463 |
|
| 2006 |
DiMichele D, Chuansumrit A, London AJ, Thompson AR, Cooper CG, Killian RM, Ross LF, Lillicrap D, Kimmelman J. Ethical issues in haemophilia. Haemophilia : the Official Journal of the World Federation of Hemophilia. 12: 30-5. PMID 16683994 DOI: 10.1111/J.1365-2516.2006.01258.X |
0.347 |
|
| 2006 |
Kimmelman J, Baylis F, Glass KC. Stem cell trials: lessons from gene transfer research. The Hastings Center Report. 36: 23-6. PMID 16544835 DOI: 10.1353/Hcr.2006.0012 |
0.452 |
|
| 2005 |
Kimmelman J, Levenstadt A. Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials. Human Gene Therapy. 16: 502-508. PMID 15871681 DOI: 10.1089/Hum.2005.16.502 |
0.426 |
|
| 2005 |
Kimmelman J, Palmour N. Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis Journal of Medical Ethics. 31: 209-214. PMID 15800361 DOI: 10.1136/Jme.2003.006247 |
0.404 |
|
| 2005 |
Kimmelman J. Recent developments in gene transfer: risk and ethics. Bmj. 330: 79-82. PMID 15637370 DOI: 10.1136/Bmj.330.7482.79 |
0.392 |
|
| 2004 |
Kimmelman J. Valuing Risk: The Ethical Review of Clinical Trial Safety Kennedy Institute of Ethics Journal. 14: 369-393. PMID 15812985 DOI: 10.1353/Ken.2004.0041 |
0.385 |
|
| Show low-probability matches. |
